|
|
Profile
|
Delegates :
Hiroki Narita |
|
Incorporated :
October 23 , 2018 |
Paid in Capital :
50 Million yen |
Employees :
人 |
Address :
3-8-3,Nipponbashihonmachi,Chuo-ku,Tokyo,1030023,Japan TOKYO
〒103-0023
|
TEL/FAX :
03-5555-6337 / |
URL：
|
Attachment :
|
Mission/Background :
AnexAPep Inc. is focusing on R&D of peptide-drug conjugate (PDC) in new therapeutic target as novel solid tumor remedy.
ANEX006 consists of D-amino acid peptide directing to AT001 (internal code), conjugated with cytotoxic agent via linker.
ANEX006 is efficiently transported to and internalized into AT001-expressing tumor cells, intracellularly cleaved and kills tumor cells selectively by the released cytotoxic agent.
ANEX006 has certain advantage over competitors and potential to become 1st-in-class.
|
|
Technology & Business
|
ANEX006 consists of D-amino acid peptide directing to AT001, conjugated with cytotoxic agent via linker.
In comparison with cytotoxic agent alone in mice models, ANEX006 showed better selective cancer therapy than its cytotoxic agent alone;Enhanced delivery of its cytotoxic agent to cancer cells more efficiently and with selectivity/Enhanced therapeutic effect (3-fold in identical injection or equivalent in 1/3 injection frequently)/Better safety profile (distribution of cytotoxic agent: Liver, 1/50; other normal tissues, <1/4)/potential to deliver to brain tumors and brain metastasis through BBB
In clinical practice, it is expected that significant improvement of response rate and clinical benefits by safely increasing dose with equal (or better) toxicity profile compared to treatment with cytotoxic agent alone.
Furthermore, since AT001 is highly expressed in a broad range of tumors including lung, colorectal and breast cancers, ANEX006 is expected to be indicated for a wide range of cancer types.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
ANEX006
|
Discovery
|
Peptide-drug conjugate (PDC) Better selective cancer therapy Enhanced delivery Enhanced therapeutic effect Better safety profile
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
We have been discussing some pharmaceutical companies regarding business collaboration under CDA.
|
|
Alliance strategy
|
We seek for opportunities of licensing-out or co-development of our lead PDC, ANEX006.
|
|
|